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Abstract
We used T2-STIR (Short Tau Inversion Recovery) cardiovascular magnetic resonance to
demonstrate carcinoid tumor metastases to the heart and liver in a 64-year-old woman with a
biopsy-proven ileal carcinoid tumor who was referred because of an abnormal echocardiogram.
Case presentation
A 64-year-old Middle-Eastern woman was referred to our
center for cardiovascular magnetic resonance (CMR) for
further evaluation of basal inferior left ventricular (LV)
wall thickening that was detected by transthoracic
echocardiography done in her home country. The
echocardiogram was done to search for cardiac valvular
manifestations of a biopsy-proven ileal carcinoid tumor.
Multiple CMR imaging sequences were obtained which
demonstrated that the basal inferior LV wall thickening
was composed of an intramyocardial mass. In addition,
there was another smaller (9 mm diameter) intramyocar-
dial mass in the free wall of the right ventricle (RV) and
there were multiple masses in the liver. All of these cardiac
and hepatic masses had the same magnetic resonance
imaging characteristics. Neither the RV mass nor the
hepatic masses were reported to be detected by echocardi-
ography. The CMR sequence which best distinguished the
metastatic carcinoid cardiac and hepatic tumors from sur-
rounding normal tissue in this case was T2-weighted Short
Tau Inversion Recovery (T2-STIR). In addition, CMR dem-
onstrated the absence of carcinoid valvular thickening. In
this case, information learned from CMR, guided cardiac
surgical and oncologic consultants' clinical decisions.
CMR methods and findings
Scans were carried out using a Siemens Sonata 1.5 Tesla
scanner. Initial localizer images using electrocardiograph-
ically-gated Half-Fourier Acquisition Single-shot Turbo
spin Echo (HASTE) showed multiple hepatic metastases
up to 65 mm × 60 mm in size, and a large intramyocardial
mass (43 mm × 35 mm × 32 mm) in the basal inferior
wall of the LV. Cine balanced Steady State Free Precession
images demonstrated that the intramyocardial mass had
fused with the posterior leaflet of the mitral valve, restrict-
ing its motion and causing moderate mitral regurgitation.
A small amount of pericardial effusion surrounding the
mass was noted, but there was no evidence of extension of
the mass into the pericardial space.
A T2-weighted Short Tau Inversion Recovery (T2-STIR)
sequence revealed the LV intramyocardial mass to have a
high signal intensity which indicates a high water content
that could be caused by active inflammation and/or
edema. The same high signal intensity signal was noted in
the hepatic masses. A small spherical intramyocardial
mass (9 mm in diameter) with the same high signal inten-
sity was identified in the free wall of the right ventricle
(RV), which had not been detected by echocardiography
nor identified as distinctly by other CMR sequences (Fig.
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1). Tissue characteristics of the myocardial masses were
similar to those of the surrounding normal myocardium
on T1-weighted imaging. Intravenous gadolinium-DTPA
contrast agent (0.1 mmol/kg) was given and after 15 min-
utes, the intracardiac masses had a patchy late gadolinium
enhancement (LGE) (Fig. 2).
No evidence of carcinoid valvular thickening was found
on either side of the heart. The right ventricle and right
atrium were normal in size and function. The left atrium
was dilated secondary to mitral regurgitation that was
attributed to the fixed posterior mitral valve leaflet. The
anterior leaflet was normal in its motion and thickness.
Discussion of diagnosis
Carcinoid tumors are neuroendocrine tumors with an
estimated annual incidence of 2 per 100,000 in the gen-
eral population. [1] They occur most frequently in the
intestine, but can also be found in the lung, bronchi or
stomach. Characteristic features of malignant carcinoid
syndrome (which are the initial presenting symptoms in
20–30% of patients) are facial flushing, secretory diarrhea
and carcinoid heart disease.
In a study of 74 patients with carcinoid heart disease [2]
all had hepatic metastases thus increasing production of
vasoactive substances and limiting the liver's ability to
inactivate them. Patients with carcinoid heart disease clas-
sically present with right-sided valvular dysfunction, char-
acterized by valvular thickening with stenosis and/or
(RV Mass) Figure 1
(RV Mass). Sections A and B use the (T2-STIR) sequence to image the right ventricular (RV) free-wall mass. Section A shows 
the bright signal of the RV mass (arrow) in the short-axis plane of the RV and the left ventricle (LV). Section B shows the dis-
tinctly bright signal of the sharply-bordered RV mass (arrow) that measures 9 mm in diameter in the four-chamber plane. Sec-
tions C and D are single frames obtained using a gradient echo cine (GRE Cine) sequence to image chamber size, valvular 
structure and wall motion; general cardiac anatomy and function. Section C shows the RV mass (arrow) and the absence of LV 
wall thickening at this mid-LV short-axis imaging plane. The basal LV is not imaged here. Section D shows that the RV mass 
(arrow) is not as distinctly outlined by this GRE Cine sequence as it is using the same four-chamber imaging plane and the T2-
STIR sequence. This GRE Cine sequence demonstrates the left atrial enlargement, but this four-chamber plane is not appropri-
ate for imaging the basal inferior LV mass.
T2 STIR T2 STIR
GRE Cine GRE Cine
9 mm
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regurgitation since the majority of primary carcinoid
tumors are in the intestine and the vasoactive substances
5-hydroxytryptamine (serotonin), 5-hydroxytryptophan,
histamine, bradykinins, tachykinins and prostaglandins,
are not inactivated in the liver with metastases and thus
pass through the right side of the heart before they are
inactivated in the lung [3]. Left-sided valvular dysfunction
can be seen in patients with a right-to-left intracardiac
shunt and an intestinal carcinoid tumor, or in others with
a lung or bronchial carcinoid tumor without an intracar-
diac shunt. In these conditions the vasoactive substances
bypass inactivation in the lung and expose the mitral and
aortic valves to potential endocardial fibrosis, valvular
thickening and dysfunction. A study that exposed rats to
long term subcutaneous serotonin demonstrated mor-
phological and echocardiographic changes similar to
those seen in human carcinoid heart disease [4]. In 8 of 11
cases of metastatic carcinoid tumor to the heart [1] there
was associated valvular thickening and fibrosis. In addi-
tion to this case and the 3 of 11 reported by Pandya [1],
there are other case reports of carcinoid tumor metastatic
to the heart, with no carcinoid valvular thickening
detected by echocardiography or CMR [5-8]. Metastatic
myocardial carcinoid has been identified in the pericar-
dium [9], but most are intramyocardial [1] and in one
case the intramyocardial metastasis involved the conduc-
tion system causing lethal complete heart block [10].
As a consequence of improvements in the treatment and
the prognosis for patients with a carcinoid tumor, the inci-
dence of carcinoid heart disease and cardiac metastases
has also increased [11]. Among patients with metastatic
carcinoid disease, the overall incidence of myocardial
metastases is about 4% [1]. Echocardiography is the most
(LV and Hepatic Masses) Figure 2
(LV and Hepatic Masses). Sections A and B are vertical long axis images of the left ventricle (LV). Section A shows the 
bright signal from the large basal inferior wall mass (arrow) using T2-STIR. Section B shows the patchy signal from the large 
basal inferior wall mass (arrow) using LGE. Sections C and D are short axis images of the heart at the level of the basal inferior 
LV mass and the liver. Section C shows that the bright signal from the LV mass (3 thin arrows) is similar to the bright signal 
from the hepatic masses (3 bold arrows) using the same T2-STIR sequence. Section D shows the patchy signal from the LV 
mass (3 thin arrows), its proximity to the posterior mitral valve leaflet, the enhanced mitral valve orifice and the patchy signal 
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commonly used method for identification of valvular car-
cinoid heart disease. Although it has been the main tech-
nique used for diagnosis of myocardial metastases, its
spatial resolution according to Pandya et al is just 1 cm
[1]. The limit of resolution of transesophageal echocardi-
ography is in the 1–3 mm range, but areas of the RV or LV
apex often are not well imaged. This finer resolution is
best appreciated when the structure is surrounded by
blood or pericardial fluid. In the case described here, basal
left ventricular thickening was recognized using echocar-
diography, but could not be easily distinguished from the
unaffected surrounding myocardial tissue. The strength of
CMR is in its multiple imaging sequences that can high-
light different tissue characteristics of tumor within an
otherwise homogeneous segment of muscle.
Metastatic tumors to the heart are 20–40 times more fre-
quent than primary tumors of the heart [12]. Intracardiac
metastases from neuoendocrine tumors of the carcinoid
type may mimic benign cardiac tumors like a myxoma
[13] which are characterized by varying signal intensity
(SI) by both T1-weighted spin-echo (SE) and T2-weighted
SE, very low SI by gradient-echo and become hyperintense
with gadolinium contrast enhancement [14].
Indium-111-labeled somatostatin receptor imaging has
been used to localize carcinoid tumors [15] and to visual-
ize carcinoid tumor myocardial metastases [16] with great
clinical utility. In addition to localization of the carcinoid
tumor, radiopharmaceutical uptake has been correlated
with tumor responsiveness to somatostatin therapy.
Nuclear imaging alone lacks fine discrimination and can-
not provide visualization of valvular anatomy and func-
tion. When the image co-registration (fusion) technique is
used, the higher resolution anatomic CT or CMR is com-
bined with the functional strength of these nuclear medi-
cine images. In an assessment of the extent of metastases
of gastrointestinal carcinoid tumors using whole-body
PET, CT, MR, PET/CT and PET/MR with particular atten-
tion to the liver, lymph nodes and bone, MR as a single
modality revealed the most liver metastases [17].
The identification and localization of carcinoid myocar-
dial metastases and the presence or absence of carcinoid
valvular disease and its severity is pivotal for planning
therapy. While some myocardial metastases are located in
regions that are amenable to excision (in this case the 9
mm RV free-wall mass), others, like the large basal inferior
LV mass attached to the posterior leaflet of the mitral
valve, are more technically challenging for the surgeon,
may be too large to remove and repair, and carry a greater
surgical mortality.
The relatively new T2-STIR technique, used to detect the
presence and extent of myocardial edema in patients with
a recent myocardial infarction, can be applied to estimate
the water content of a cardiac mass [13]. The high signal
intensity of carcinoid myocardial metastasis using the T2-
STIR sequence was first described by Puvaneswary et al
[18] in a case in which the tumors imaged by CMR
involved the pericardium, were large and were imaged by
echocardiography. In the present case, the importance of
this T2-STIR sequence is highlighted by its ability to detect
a small carcinoid myocardial metastasis that lacked peri-
cardial involvement that was not detected by echocardiog-
raphy. As a single modality, only CMR can offer fine
spatial resolution, tissue characterization, assessment of
valvular structure and function, detection and quantifica-
tion of cardiac and hepatic metastases and assessment of
myocardial function in one test.
Treatment and management
Surgical and oncologic consultants conferred after review-
ing the case and the data provided by the CMR imaging.
Considering the absence of cardiac symptoms, the pres-
ence of multiple cardiac lesions, the size of the basal infe-
rior LV mass, its involvement of the posterior mitral valve
leaflet, and the multiple large hepatic masses, a surgical
cure was not attainable and the surgical risk was high,
without immediate clinical gain. A decision was made to
manage the patient without surgery. She left London for
medical treatment at home.
Conclusion
In this case, echocardiography done to determine the
source of a systolic murmur did not find carcinoid valvu-
lar disease, but rather a curious basal inferior LV thicken-
ing. CMR, and especially the bright signal from the
carcinoid myocardial metastases using the T2-STIR
sequence, identified the large LV mass and a smaller RV
mass that was not detected by echocardiography, in the
absence of a pericardial effusion. In addition, the identifi-
cation of hepatic metastases, the tissue characterization of
the tumor masses by LGE, and the assessment of myocar-
dial and valvular function made CMR the single best test
for assessing the cardiac and hepatic sequellae of meta-
static carcinoid tumor.
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